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Assessing Physical Function and Fatigue in Patients Selected
to Undergo Bone Marrow Transplant.
Adrian Cristian MD, MHCM1,2. 1 Cancer Patient Support
Services, Miami Cancer Institute, Miami, FL; 2 Marco Ruiz, Miami
Cancer Institute, Miami, FL
Introduction: The assessment of baseline physical function
should be an important and integral component in the selec-
tion of patients to undergo a bone marrow transplant. This
assessment can establish a baseline level of function that can
be tracked as the person undergoes cancer treatment as well
as during the survivorship period. It can also be used to iden-
tify physical impairments early that can subsequently be
treated rehabilitative interventions to minimize activity limi-
tations and participation restrictions. Simple tests are available
and can be useful in clinical settings.
Objectives: The aim of this work is to share one center’s expe-
rience in the collection and analysis of data pertinent to physi-
cal function in patients referred for pre-bone marrow
transplant evaluation.
Methods: Retrospective chart review of patients referred
for an initial consultation in a cancer rehabilitation clinic in
a cancer institute. The medical charts of 29 patients
selected to undergo bone marrow transplant (AML/ALL-4,
Lymphoma-11 and myeloma 14) were reviewed. Mean age
was 55. Gender: 12 female and 17 male. The following
information was reviewed: a) Patient Reported Outcome
Measure Information System (PROMIS) Physical Function
Short form and Fatigue short form b) Timed up and Go
(TUG) test c) Sit to stand in 30 seconds test (STS-30) d)
Grip Strength (in Kg)using a hand held dynamometer and
e) 4 stage balance test. Values obtained during clinic visits
were compared to available normative data for factors such
as age and gender. These tools were selected because they
are validated instruments that are easily collected in a
physician’s clinic.
Results: Based on the PROMIS Physical Function score
results, 9/28 pre-BMT (32%) had an impaired physical func-
tion. Based on the PROMIS-Fatigue score results, 6/28 pre-
BMT patients (21%) complained of significant fatigue. STS-
30 results: 13/28 (46.4%) patients had normal scores for
age and gender; 15/28 (53.6%) participants had abnormal
scores for age and gender. Score for 1 participant was not
available. Grip strength results: 17/27 (63%) patients had
normal values for age and gender, 10/27 (37%) patients had
normal values for age and gender. Scores for 2 participants
were not available. 4 stage balance test: 28/29 (96.6%) par-
ticipants had a normal balance and 1/29 (3.4%) participants
had an impaired balance.
Conclusion: Assessment of physical function should be an
integral part of the evaluation of patients prior to bone mar-
row transplant. Several instruments can be easily incorporated
into a clinical setting and the information gathered can be very
useful in directing need for additional interventions and can
also serve as a baseline. Grip strength and sit to stand tests are
easy to perform and can be very useful in assessment of physi-
cal function.
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Metabolic Alterations in Adult Long-Term Survivors after
Hematopoietic Stem Cell Transplantation
Manuel Ardila-Baez1, Edwin Wandurraga1,2, Sergio Serrano1,
Maria Luna-Gonzalez1, Luis A. Salazar1,2, Sara I. Jimenez1,2,
Manuel Rosales2, Angela M. Pe~na1,2, Xueyi Chen1,
Maria A. Chacon3, Juan J. Rey1, Claudia Sossa1,2. 1 Universidad
Autonoma de Bucaramanga, Bucaramanga, Colombia; 2 Clínica
FOSCAL, Bucaramanga, Colombia; 3 Universidad Industrial de
Santander, Bucaramanga, Colombia
Introduction: Hematopoietic stem cell transplantation (HSCT)
is an option treatment for many types of hematologic diseases.
However, HSCT leads to short- and long-term complications.
Endocrinology complications are one those and even if is not
the most common group of complications, their diagnoses and
treatment can improve the quality of life in the patients.
Objective: To determine the cumulative incidence of meta-
bolic alterations after 1st, 3rd and 5th year of HSCT in patients
treated in a Colombian population.
Methods:We conducted an analytical and observational retro-
spective cohort of adult patients treated with autologous and
allogeneic HSCT at a fourth level referral center in Colombia
from 2009 to 2018. The evaluated metabolic complications
were metabolic syndrome, hypertriglyceridemia, low HDL
cholesterol, hypercholesterolemia, atherogenic dyslipidemia,
overweight, obesity, prediabetes, diabetes mellitus, hyperten-
sion and hyperuricemia.
Results: A total of 217 patients were included, 53% were men
and mean age was 46 years. 155 (71.4%) patients had autolo-
gous HSCT and 62 (28.6%) patients had allogeneic HSCT.
Results for the 1st year were obtained from 171 patients, for
3rd year from 68 patients and 5th year from 20 patients. By
type of transplant, the highest cumulative incidence in the
group of patients treated with autologous HSCT was over-
weight (43%, 60.5% and 69%) followed by obesity (9.2%, 17.6%
and 69%), while hypercholesterolemia presented the highest
cumulative incidence (38.4%, 52% and 53.8%) followed by low
HDL cholesterol (44%, 46% and 46%) in the group of patients
treated with allogenic HSCT. The results of the evaluated alter-
ations are shown in the attached figures.
Conclusion: Metabolic alterations are an important group of
complications that needs to be taken into account even before
and after the HSCT so an adequate prevention and treatment
can be stablished, leading to decrease the risk of mortality in
this group of patients. This study also suggests differences
between the cumulative incidence of metabolic disease by
type of transplant.
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Cardiovascular Disease Risk Assessment and Management
in Survivors of Allogeneic Hematopoietic Cell
Transplantation
Christina S Ferraro MSN, APRN-CNP, BMTCN1,
Theresa A. Urban PharmD2, Mariana Lucena PharmD2,
Kelly Gaffney PharmD2, Navneet S. Majhail MD, MS3,
Betty K. Hamilton MD3. 1 Blood & Marrow Transplant Program,
Cleveland Clinic, Cleveland, OH; 2 Pharmacy, Cleveland Clinic,
Cleveland, OH; 3 Blood and Marrow Transplantation, Department
of Hematology and Medical Oncology, Taussig Cancer Institute,
Cleveland Clinic, Cleveland, OH
Long-term survivors of allogeneic hematopoietic cell trans-
plantation (HCT) are at greater risk for developing late effects,
with increased risk of mortality compared to the general popu-
lation. This includes a 2-3 fold increased risk of metabolic syn-
drome and cardiovascular disease. While screening and
appropriate treatment for metabolic syndrome and CVD is rec-
ommended for long-term HCT survivors, specific guidelines in
this high risk population is limited.
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